- CSR Summary Not Yet Available
- NCT00086112
- Primary Citation
- Data Specification Not Available
Trial Information
Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaBehaviors and Mental DisordersEnrollment301% FemaleN/A% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-ANX-301Data PartnerJohnson & JohnsonCondition StudiedAnxiety DisordersMean/Median Age (Years)N/A
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4575 : A NOVEL METHOD TO SUMMARIZE SAFETY IN CLINICAL TRIALS USING PHARMACOLOGICAL CLASS-RELATED RISKS IN FAERS
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.